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1086-65 Reduced hlyocardial Brain Natriuretic Peptide 
Expression and Collagen Deposition Following 
Ventricular Assist Device Support for Heart Failure 
Brett E. Fenster, Michael B. Fowler, Yin-Gail Yee, Andrew Connolly, Philip S. Tsao, 
Stanford University, Stanford, CA 
Background: Unloading of the myocardium with ventricular assist devices (VAD) 
induces adaptive remodeling potentially through alterations in extracellular matrix com- 
ponents. A biochemical marker of volume overload, pathologic hypertrophy. and ventric- 
ular dysfunction, brain natriuretic peptide (BNP) plasma levels are reduced following 
VAD therapy and may herald myocardial functional recovery. However, the role of tissue 
BNP in regression of myocardial fibrosis is unclear. We investigated the relationship 
between myocardial expression of BNP, pro-alphalA(2) collagen (COL IAZ), and trans- 
forming growth factor beta (TGF-B), a known regulator of vascular fibrosis, in the sening 
of ventricular unloading. 
Methods: Left ventricular myocardium from 11 patients with end stage hearl failure was 
obtained at the ttme of VAD implantation and at cardiac transplant. Etiologies for heart 
failure included idiopathic dilated (6), ischemic (4) and hypertrophic (1) cardiomyopa- 
thies. VAD treatment duration ranged from 4 to 323 (Mean 96 days). Real time quantita- 
tive PCR was used to determme differential expression of BNP, TGF-8, and COL IAZ. 
PCR results were reported as the mean threshold cycle normalized for expression of an 
internal control (ribosomal 18s protein). Specimens were evaluated by a blinded patholo- 
gist for perivascular fibrosis and reported on a scale from 0 to 3 (3 = severe). Statistical 
significance in differential expression of BNP, TGF-B, and COL IA2 expression post-VAD 
was assessed using a paired student’s t-test. 
Results: Ventricular unloading resulted in a significant decrease in both myocardial BNP 
expression (Pre-VAD ,401 +/- 4.44 vs. Post-VAD 4.13 +I- 3.97, p ,031) as well as fibrosis 
(Pre-VAD 1.71 +I- ,756 vs. Post-VAD 1.14 +I- .69, p .03). Regression analysis demon- 
strated significant positive correlations between BNP and TGF-B (R ,999, p < .OOOl), 
BNP and COL IA2 (R ,999, p < .OOOl), and TGF-B and COL IA2 (R ,999, p < .OOOl). 
Conclusions: Ventricular unloading with VAD reduces myocardial BNP, TGF-B, and col- 
lagen expression in association with histologic regression of fibrosis. 
1086-66 Mechanical Circulatory Support: An l&Year Experience 
With Over 460 Patient Years of Support 
R. Hetzer, R. Koerfer, D. Hammel, P. Partner. P. Oyer, P. McCarthy, S. Lansman, m 
Mussivand on behalf of the Novacor LVAS Investigators, University of Ottawa Healt -3 
Institute, Ottawa. ON, Canada 
Backgound: Mechanical circulatory support (MCS) devices have evolved from a prima- 
rily resuscitative measure to a viable treatment for end-stage healt failure patients. An 
16.year clinical experience representing over 460 patient years of support from a single 
device (Novacor LVAS) was retrospectively reviewed. Methods: Utilizing data from the 
international registry, the patient characteristics and outcomes were analyzed for 1363 
patients at over 90 international centers. Results: The mean age at time of implant was 
48 years (12-78 years). Etiology was non-ischemic cardiomyopathy in 776 (57%), 
ischemic heart disease in 439 (32%), acute myocardial infarction in 56 (4%) and other 
(post-cardiotomy. myocarditis, etc.) in 92 (7%). The intent to treat was as a bridge to 
transplantation in 93% of patients, as a bridge to recovery in 4% and as a “Destination 
Therapy” in 3%. Currently, 70 of these patients are supported, 706 patients survived to 
transplantation, and 39 patients were weaned from the device following myocardial 
recovery. The mean support duration was 129 days (0 - 1613 days), and over 460 years 
of patient suppoti has been accumulated. There were no patient deaths due to device 
failure and after the initial high risk period post-implant (first 3 months), 70.75% of 
patients achieved a favorable outcome (Le. transplantation or weaning). The majority of 
long-term recipients (80% of those supported > 30 days) were able to be discharged from 
hospital and return to near normal life activities. Conclusions: 1) This substantial experi- 
ence has demonstrated MCS can provide an effective therapeutic option for end-stage 
heart failure, 2) Enhanced quality of life has been demonstrated with patients discharged 
from hospital and able to return to normal life activities, 3) Overall device safety has been 
demonstrated with no patient deaths due to device failure, and 4) Long-term device dura- 
bility has been demonstrated with patients supported for over 4 years on a single device. 
These findings support widened use of MCS, both for short-term use as a bridge to trans- 
plant and longer-term support as a potential ‘“destination therapy”. 
* Due to space limitation only investigators with more than 50 patients are listed 
1086-67 Reduced Myocardial Blood Flow During Left Ventricular 
Assist Device Support May Lead to Premature Closure 
of Coronary Artery Bypass Grafts 
Simon Mavbaum, Sean Penney, Yoshifumi Naka. Donna Man&i, Mehmet Oz. Steven R. 
Bergmann, Columbia Umversity, New York, NY 
Background: Patients who fail to wean from cardiopulmonary bypass following cardiac 
surgery can be supported hemodynamically with a left ventricular assist device (LVAD). 
Because LVAD support results in profound pressure and volume unloading of the left 
ventricle, we souaht to determine what effect this reduction in workload would have uoon 
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myocardial oxygen consumption (MVOZ), myocardial blood flow (MBF) and bypass graft 
patency. 
Methods: Positron emission tomography (PET) scanning was performed in 9 LVAD 
patients (age 39+14 years) with non-ischemic cardiomyopathy (DCM) and 12 normal 
subjects, wng C-l 1 acetate to measure MV02 and N-13 ammonia to measure MBF. 
Five other patients (age 56*12 years) with coronary disease (CAD), who underwent cor- 
onary artery bypass grafting (CABG) and required LVAD implantation for post-cardlot- 
omy shock (with patent grafts), had coronary angiography performed during device 
support. 
Results: PET scanning in the DCM patients was performed 65*29 days following LVAD 
implantation and revealed a significant reduction in both MV02 (0.03* 0.01 vs. 
0.06iO.01 min.1; pcO.005) and MBF (0.49iO.15 vs. 0.66iO.17 mlis/min; ~~0.03) com- 
pared to normal subjects. Coronary angiography in the CAD patients was performed 
115il26 days after CABG and LVAD implantation. Twelve of the 16 bypass grafts (75%) 
were either totally occluded or significantly stenosed. 
Conclusion: In a cohort of patients with DCM, LVAD support reduced both MV02 and 
MBF. Autoregulatory mechanisms that match MBF with MV02 may explain the observed 
downregulation in blood flow that followed lefl ventricular unloading. Low MBF may be 
implicated in the premature graft failure observed in our CABG patients and may nega- 
tively impact the potential for myocardial recovery and device weaning in this population. 
1086-68 Age Is Not a Factor in Survival of Patients Undergoing 
Left Ventricular Assist Device Placement as Destination 
Therapy: The REMATCH Experience 
Yoshifumi Naka. Brian Jaski, Cy Tector. Lynne Warner Stevenson, Edward Rames, 
William Holman. James ChewTson Fana. Susan Wriaht. Anita Tiernev. Alan Weinbera. 
Laura Damme, Karen Hall, 0. Howard Fy&ier, REMnidH Study Gro&, Columbia -’ 
University. New York, NY 
Objective: Left ventricular assist device (LVAD) implantation as destination therapy has 
been shown to provide increased survival and improved quality of life for patients with 
end stage heart failure who do not qualify for heart transplantation. Many such patients 
fall into the elderly category with 65 years of age being a frequent criteria used for exclu- 
sion from the transplant list. We evaluated the outcomes of elderly patients undergoing 
LVAD placement as destination therapy for end-stage heart failure and compared their 
results to those of the younger population. Mthods: As part of the randomized evaluation 
of mechanical assistance for the treatment of congestive heart failure (REMATCH) study, 
68 patients were randomized to receive LVAD Implantation as treatment for end-stage 
heart failure. We further stratified this LVAD patient group according to age and com- 
pared outcomes between the young (~65) and the elderly (x65) patients. Results: 68 
patients in the study received LVADs. Median age for the population was 67. The group 
contained 19 young and 49 elderly patients. The preoperative risk factors between the 
two groups were similar with exception of higher pulmonary artery pressures in the young 
(~~0.05) and greater use of aspirin in the old (p<O.O5). The medtan length of hospital stay 
for survivors was 28 days and 33 days for the young and the old respectively (p=O.l83). 
The hospital mortality rate was 21 .l% (n=4) and 34.7% (n=l7) for the young and old 
respectively (p=O.275). We compared the two groups by Kaplan-Meier actuarial survival 
using the Log Rank test, and found no significant difference (p=O.596). Conclusions: 
Our data analysis shows that older patients receiving LVADs do not have a decreased 
rate of overall swival when compared to the younger patients. In addition to that, hospi- 
tal mortality and length of hospital stay in this patient population is not significantly pro- 
longed. LVAD implantation in the elderly population with end stage heart failure is a 
viable option. 
1086-69 Cardiac Recovery During 30 Days of Support With a Left 
Ventricular Assist Device. Preliminary Results From the 
LVAD Working Group 
Simon Mavbaum 0. H. Frazier, Randall C. Starling, Leslie Miller, Srlnivas Murali, Keith 
D. Aaronson, Kenneth Margulies, Susan McRee, Guillermo Terre, on behalf of the LVAD 
Working Group, Columbia University, New York, NY, Baylor College of Medicine, 
Houston, TX 
Background: The proportion of patients with chronic heaft failure demonstrating cardiac 
recovery during left ventricular assist device (LVAD) support is unknown.The LVAD 
Working Group Recovery Study is a multwenter prospective study of myocardial recov- 
ery during LVAD support. 
Methods: 8 centers participate in the study and patients are enrolled 30 days after LVAD 
implantation. Pre-LVAD clinical variables are collected from chart review and patients 
undergo monthly echocardlographic assessment of cardiac function during full and par- 
t!al (4 IWmin) LVAD support. Dobutamine echocardiograms and exercise testing with 
hemodynamic measurements are performed I” patients demonstrating improvement in 
resting function. Patients undergoing LVAD explantation for recovery are followed and 
their survival compared to those patients undergoing transplantation. Paired myocardial 
tissue samples from implant and explant and serial blood samples are stored m a collec- 
tive tissue and blood bank. Investigations utilizing these samples ~111 characterize the 
response of the failing myocardium to mechanical unloading. We will screen clinical and 
biological markers that may be used to identify patients with sustained cardiac recovery. 
Results: Twenty seven patients underwent LVAD Implantation during the initial 6 months 
of study. 16 patients were ineligible for study at 30 days, because they were transplanted 
(n-9), had died (n=3) or were supported with inotropes (n=4). 11 patients (8 DCM, 3 
CAD) underwent echocardiographlc assessment at 30 days post implantation. Left ven- 
tricular ejection fraction (LVEF) pre-LVAD was 17* 6%, at 30 days with full device sup- 
port was 33+7% and with partial support was 32*10%. Three patients met crlterla for 
recovery at 30 days (LVEF>IO% with partial support). 
Conclusions: Our initial experience demonstrates that a multi-center prospective study of 
myocardial recovery is feasible. This study will assess the potential for use of LVADs as 
